Abstract:ABSTRACT Drug-resistant bacteria are a serious threat to human health as antibiotics are gradually losing their clinical efficacy. Comprehending the mechanism of action of antimicrobials and their resistance mechanisms plays a key role in developing new agents to fight antimicrobial resistance. The lipopeptide daptomycin is an antibiotic that selectively disrupts Gram-positive bacterial membranes, thereby showing slower resistance development than many classical drugs. Consequently, it is often used as a last resort antibiotic to preserve its use as one of the least potent antibiotics at our disposal. The mode of action of daptomycin has been debated but was recently found to involve the formation of a tripartite complex between undecaprenyl precursors of cell wall biosynthesis and the anionic phospholipid phosphatidylglycerol. BceAB-type ABC transporters are known to confer resistance to antimicrobial peptides that sequester some precursors of the peptidoglycan, such as the undecaprenyl pyrophosphate or lipid II. The expression of these transporters is upregulated by dedicated two-component regulatory systems in the presence of antimicrobial peptides that are recognized by the system. Here, we investigated whether daptomycin evades resistance mediated by the BceAB transporter from the bacterial pathogen Streptococcus pneumoniae . Although daptomycin can bind to the transporter, our data showed that the BceAB transporter does not mediate resistance to the drug and its expression is not induced in its presence. These findings show that the pioneering membrane-active daptomycin has the potential to escape the resistance mechanism mediated by BceAB-type transporters and confirm that the development of this class of compounds has promising clinical applications. IMPORTANCE Antibiotic resistance is rising in all parts of the world. New resistance mechanisms are emerging and dangerously spreading, threatening our ability to treat common infectious diseases. Daptomycin is an antimicrobial peptide that is one of the last antibiotics approved for clinical use. Understanding the resistance mechanisms toward last-resort antibiotics such as daptomycin is critical for the success of future antimicrobial therapies. BceAB-type ABC transporters confer resistance to antimicrobial peptides that target precursors of cell-wall synthesis. In this study, we showed that the BceAB transporter from the human pathogen Streptococcus pneumoniae does not confer resistance to daptomycin, suggesting that this drug and other calcium-dependent lipopeptide antibiotics have the potential to evade the action of this type of ABC transporters in other bacterial pathogens.

Elucidating Daptomycin's Antibacterial Efficacy: Insights into the Tripartite Complex with Lipid II and Phospholipids in Bacterial Septum Membrane

Ca2+-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids

Lipopeptide daptomycin: Interactions with bacterial and phospholipid membranes, stability of membrane aggregates and micellation in solution

The effects of daptomycin on cell wall biosynthesis in Enterococcal faecalis

High-speed atomic force microscopy highlights new molecular mechanism of daptomycin action

The last resort antibiotic daptomycin exhibits two independent antibacterial mechanisms of action

Molecular basis of cell membrane adaptation in daptomycin-resistant Enterococcus faecalis

Daptomycin: mechanisms of action and resistance, and biosynthetic engineering

Daptomycin: Putative New Mechanisms of Action and Resistance Evolved from Transcriptome Data Mining

Antibacterial Mechanism of Daptomycin Antibiotic Against Staphylococcus Aureus Based on a Quantitative Bacterial Proteome Analysis.

Exploring the Binding Mechanisms of Diaminopimelic Acid Analogs to Meso-Diaminopimelate Dehydrogenase by Molecular Modeling.

Daptomycin: Mechanism of action, mechanisms of resistance, synthesis and structure-activity relationships

Molecular Mechanisms Underlying Daptomycin Resistance

Structure elucidation of the daptomycin products generated upon heterologous expression of the daptomycin resistance gene cluster drcAB

The Dual Mode of Antibacterial Action of the Synthetic Small Molecule DCAP Involves Lipid II Binding

Daptomycin avoids drug resistance mediated by the BceAB transporter in Streptococcus pneumoniae

β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models

Purification of daptomycin binding proteins (DBPs) from the membrane of Enterococcus hirae

Defective pgsA contributes to increased membrane fluidity and cell wall thickening in S. aureus with high-level daptomycin resistance

Daptomycin: one of the cyclo-lipopeptide antibiotics

Multifunctional Pharmaceutical Effects of the Antibiotic Daptomycin